Fuda Cancer Hospital, Guangzhou: all 116 studies
Page 1 of 2. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- CAR-T Cell Immunotherapy for GD2 Positive Glioma PatientsWithdrawnNCT04406610Phase 1/2
- Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular CarcinomaCompletedNCT04393220Phase 2
- Very Small Embryonic-like Stem Cells for OvaryWithdrawnNCT03985462Phase 1/2
- Very Small Embryonic-like Stem Cells for Facial Skin AntiagingWithdrawnNCT03976206Phase 1/2
- Very Small Embryonic-like Stem Cells for Knee OsteoarthritisWithdrawnNCT03975101Phase 1/2
- Very Small Embryonic-like Stem Cells for Erectile DysfunctionWithdrawnNCT03973021Phase 1/2
- Hydrogen Gas for Cancer RehabilitationCompletedNCT03818347Not applicable
- Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPCCompletedNCT03673137Phase 2/3
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric CancerWithdrawnNCT03554395Phase 2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney CancerWithdrawnNCT03540199Phase 2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal CancerWithdrawnNCT03524274Phase 2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast CancerWithdrawnNCT03524261Phase 2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic CancerWithdrawnNCT03509298Phase 2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung CancerWithdrawnNCT03501056Phase 2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver CancerWithdrawnNCT03484962Phase 2
- Mix Vaccine for Metastatic Sarcoma PatientsCompletedNCT03357315Phase 1/2
- Mix Vaccine for Metastatic Kidney CancerCompletedNCT03357289Phase 1/2
- Mix Vaccine for Metastatic Colorectal CancerCompletedNCT03357276Phase 1/2
- Bioinformation Therapy for Intestinal CancerCompletedNCT03350490Phase 2/3
- Bioinformation Therapy for Gastric CancerCompletedNCT03350477Phase 2/3
- PENS or TENS for Pain in Liver CancerCompletedNCT03338543Not applicable
- PENS or TENS for Pain in Pancreatic CancerCompletedNCT03331055Not applicable
- CAR-T Cell Immunotherapy for GD2 Positive Glioma PatientsWithdrawnNCT03252171Phase 1/2
- Bioinformation Therapy for Breast CancerCompletedNCT03240224Phase 2/3
- Bioinformation Therapy for Pancreatic CancerCompletedNCT03239184Phase 2/3
- Bioinformation Therapy for Lung CancerCompletedNCT03239171Phase 2/3
- Bioinformation Therapy for Liver CancerCompletedNCT03239158Phase 2/3
- Safety and Efficiency of γδ T Cell Against Lung CancerCompletedNCT03183232Phase 1/2
- Safety and Efficiency of γδ T Cell Against Liver CancerCompletedNCT03183219Phase 1/2
- Safety and Efficiency of γδ T Cell Against Breast CancerCompletedNCT03183206Phase 1/2
- Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic CancerCompletedNCT03180437Phase 1/2
- High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal CancerCompletedNCT03008499Phase 1/2
- Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver CancerCompletedNCT03008343Phase 1/2
- High-activity Natural Killer Immunotherapy for Small Metastases of Tongue CancerCompletedNCT03008330Phase 1/2
- High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic CancerCompletedNCT03008304Phase 1/2
- High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung CancerCompletedNCT03007875Phase 1/2
- High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal CancerCompletedNCT03007836Phase 1/2
- High-activity Natural Killer Immunotherapy for Small Metastases of MelanomaCompletedNCT03007823Phase 1/2
- Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic CancerCompletedNCT02981719Not applicable
- Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid TumorsCompletedNCT02857920Phase 1/2
- Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid TumorsCompletedNCT02853903Phase 2
- Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue CancerCompletedNCT02849379Phase 1/2
- Combination of Cryosurgery and NK Immunotherapy for Recurrent SarcomaCompletedNCT02849366Phase 1/2
- Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian CancerCompletedNCT02849353Phase 1/2
- Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical CancerCompletedNCT02849340Phase 1/2
- Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal CancerCompletedNCT02849327Phase 1/2
- Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal CancerCompletedNCT02849314Phase 1/2
- Combination of Cryosurgery and NK Immunotherapy for Tumors in Transplanted LiverCompletedNCT02849015Phase 1/2
- Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung CancerCompletedNCT02845856Phase 1/2
- Combination of Cryosurgery and NK Immunotherapy for Advanced Breast CancerCompletedNCT02844335Phase 1/2
- Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung CancerCompletedNCT02843815Phase 1/2
- Combination of Cryosurgery and NK Immunotherapy for Advanced Liver CancerCompletedNCT02843802Phase 1/2
- Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney CancerCompletedNCT02843607Phase 1/2
- Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal CancerCompletedNCT02843581Phase 1/2
- Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid TumorsCompletedNCT02843204Phase 1/2
- Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast CancerCompletedNCT02843126Phase 1/2
- Combination of Rituximab and NK Immunotherapy for B LymphomaCompletedNCT02843061Phase 1/2
- Cryotherapy Combine Icotinib for Advanced NSCLC TreatmentCompletedNCT02744664Phase 4
- CAR-T Cell Immunotherapy for HCC Targeting GPC3WithdrawnNCT02723942Phase 1/2
- Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic CancerCompletedNCT02718859Phase 1/2
- CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma PatientsWithdrawnNCT02575261Phase 1/2
- Chimeric Antigen Receptor-Modified T Cells for Breast CancerWithdrawnNCT02547961Phase 1/2
- CD19-targeting CAR T Cells for B Cell LymphomaWithdrawnNCT02547948Phase 1/2
- Liver Cancer HepaSphere Combined With CryosurgeryCompletedNCT02545556Phase 1/2
- HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal CarcinomaCompletedNCT02523430Phase 1/2
- HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Breast CancerCompletedNCT02523417Phase 1/2
- HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung CancerCompletedNCT02523404Phase 1/2
- HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical CarcinomaCompletedNCT02523365Phase 1/2
- The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK TreatmentCompletedNCT02450448
- The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK TreatmentCompletedNCT02450435
- The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK TreatmentCompletedNCT02450422
- The Detection of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Undergoing Cryosurgery Combined With DC-CIK TreatmentCompletedNCT02450357
- HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic CancerWithdrawnNCT02449967Phase 1/2
- Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic CarcinomaNo longer availableNCT02449135
- Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung CarcinomaCompletedNCT02449122Phase 1/2
- Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver CarcinomaCompletedNCT02449109Phase 1/2
- HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver CancerCompletedNCT02447263Phase 1/2
- Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral NeoplasmsCompletedNCT02430779Not applicable
- Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases(Close to Nerve)CompletedNCT02430766Not applicable
- Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function InsufficiencyCompletedNCT02430753Not applicable
- Irreversible Electroporation(IRE) For Unresectable Esophageal NeoplasmsCompletedNCT02430701Not applicable
- Irreversible Electroporation(IRE) For Unresectable Extremities NeoplasmsCompletedNCT02430688Not applicable
- Irreversible Electroporation(IRE) For Unresectable Laryngeal NeoplasmsCompletedNCT02430675Not applicable
- Irreversible Electroporation(IRE) For Unresectable Gallbladder NeoplasmsCompletedNCT02430662Not applicable
- Irreversible Electroporation(IRE) For Unresectable Prostatic NeoplasmsWithdrawnNCT02430649Not applicable
- Irreversible Electroporation(IRE) For Unresectable Stomach NeoplasmsCompletedNCT02430636Not applicable
- Irreversible Electroporation(IRE) For Unresectable Urinary Bladder NeoplasmsCompletedNCT02430623Not applicable
- Irreversible Electroporation(IRE) For Uterine Cervical NeoplasmsCompletedNCT02430610Not applicable
- Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis NeoplasmsCompletedNCT02430597Not applicable
- Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)CompletedNCT02425748Phase 1/2
- Safety and Efficiency of γδ T Cell Against Hepatocellular Liver CancerCompletedNCT02425735Phase 1/2
- Irreversible Electroporation(IRE) For Unresectable Rectal NeoplasmsCompletedNCT02425059Not applicable
- Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)CompletedNCT02418481Phase 1/2
- The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK TreatmentCompletedNCT02416635
- The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK TreatmentCompletedNCT02412384
- The Detection of CTCs in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.CompletedNCT02406846
- Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver FunctionCompletedNCT02352935Not applicable
- Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic CancerCompletedNCT02343835Not applicable
- Percutaneous Irreversible Electroportion for Unresectable Breast CancerCompletedNCT02340858Not applicable
- Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma PatientCompletedNCT02338804Phase 1/2